John Samellas’ Post

✨ Breakthrough for Patients with Medication Adherence Challenges ✨ Trelagliptin, a once-weekly DPP-4 inhibitor, is revolutionizing type 2 diabetes management for patients who struggle with medication adherence. Medication adherence is a significant challenge for many patients, leading to suboptimal treatment outcomes and increased healthcare costs. With Trelagliptin's once-weekly dosing, patients can now enjoy improved glucose control and reduced cardiovascular risk with fewer dosing burdens. This breakthrough offers new hope for patients who have struggled with daily or multiple daily doses, enabling them to better manage their condition and improve their quality of life. #MSL #MedicalAffairs #GetzPharma

Looking for a way to streamline your diabetes care workflow and easily access all your patient data across all major CGMs and insulin pumps? Find your solution at booth 332 at #ADCES24 with SweetSpot!

Innovative patents on patient care and quality of life. #ExamplesAndImpact Insulin Pump (U.S. Patent No. 6,248,093) 🌟 #InsulinPumpPatent 🏀Enhanced Patient Compliance: Simplified insulin administration, improving adherence to diabetes management. 🏀Innovative Delivery System: Provided a more precise and controlled method of insulin delivery, reducing complications associated with diabetes.

If you are living with #T1D and using insulin injections, you know how challenging it is to balance insulin doses, carbs, and glucose levels. That's why I switched to the #InPen, a smart insulin pen system that connects to my phone.   The InPen app will: ✨ track my active insulin (insulin on board) ✨ remind me when to dose before meals ✨ calculate personalized doses based on my glucose levels and carb intake    Gone are the days of me having to guess! But that's not all. With the InPen, I get a digital logbook that syncs with my CGM to create a detailed report of my sensor glucose. This information has helped me and my healthcare provider make informed decisions about my treatment. 👋 Say goodbye to traditional insulin pens and hello to smarter diabetes management! #SponsoredByMedtronic #InPen #MedtronicChampion #T1D #DiabetesManagement #SmartInsulinPen Medtronic Diabetes

Case Study: Enhancing Patient Experience in Titration of Basal Insulin for Type 2 Diabetes Patients Discover how we collaborated with a multinational market research and consulting firm to tackle challenges and deliver exceptional insights. With a focus on understanding patient barriers and evaluating the potential benefits of a smart device, we paved the way for improved communication strategies and patient empowerment. From close collaboration with the end client to quick turnaround times and a comprehensive understanding of project objectives, we went above and beyond to ensure success. Explore our case study today > https://hubs.ly/Q02wMGXC0 #CaseStudy #Type2Diabetes #HealthcareResearch #MedPlanetInsights

We published a new case study on Type 2 Diabetes, I invite you to read below the challenges and the outcome :)

🎙️ Dive into the world of diabetes management with the latest episode of Pharmland! Hosts J Bradley Nelson and Thomas Davies sat down with Langley Kyle to explore the world of GLP-1 medications. From blood sugar control to cardiovascular protection, learn how these drugs are transforming treatment. Plus, get insights into how their popularity is driving shortages and what that means for plan sponsors. Subscribe & listen here: https://rxbene.fit/3UnSTmi #PharmlandPodcast #DiabetesManagement #GLP1Medications

🌟Chapter 3 of the ATTD Yearbook 2023 is here! We’re excited to highlight "New Insulins, Biosimilars, and Insulin Therapy" by Lutz W. Heinemann. 📘This chapter offers a deep dive into the next generation of insulin treatments and their impact on diabetes care. Watch this enlightening chapter presented at #ATTD2024 and stay tuned for more to come➡️ https://bit.ly/3PlIKUJ #DiabetesTech #DiabetesManagment #ATTDYearbook #InsulinTherapy #DiabetesAdvances

May's focus is on Rybelsus and Jardiance, two medications used in type 2 diabetes management: Rybelsus (Semaglutide Oral): - The first oral GLP-1 receptor agonist for type 2 diabetes. - Helps lower blood sugar and may aid in weight loss. - Taken once daily in pill form. Jardiance (Empagliflozin): - A medication from the SGLT2 inhibitor class. - Helps the kidneys remove glucose from the bloodstream. - Also reduces the risk of heart-related death in type 2 diabetes patients. Both medications have unique mechanisms and benefits. Consult your healthcare provider to determine which is more suited to your health needs. The Rx Advocates can assist in accessing these medications affordably. Contact us today to see if you qualify for medication assistance: 844-559-8331 #DiabetesManagement #RybelsusVsJardiance #Type2Diabetes

Empower yourself with the right knowledge of Insulin Injection Techniques through our comprehensive PreOp® Patient Education video. Grasp the essentials of Insulin Therapy, Insulin Dosing, and achieving optimal Blood Glucose Control. 💉🎥Enhance your Insulin Injection SkillsExplore the significance of Hypoglycemia awareness into the best practices for Insulin Self-Administration Invest in your health by learning the right insulin injection practices. #HealthEducation #DiabetesMellitus #preop | Watch Full Video | https://lnkd.in/eyaxV3jc